Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier ...

Precision-designed using Recursion’s generative AI and active learning platform to optimize for non-covalent binding and ADME/PK, potentially delivering a broader therapeutic window, reduced off ...

Ray further emphasized that REC-3565, currently in Phase 1 trials and developed using Recursion’s advanced AI platform, would not have been conceived through traditional human design methods.

Ray further emphasized that REC-3565, currently in Phase 1 trials and developed using Recursion’s advanced AI platform, would not have been conceived through traditional human design methods.

Recursion had been a fairly popular biotech stock, due to its significant use of artificial intelligence (AI) functions to discover new drugs. However, those results put quite a damper on sentiment.